论文部分内容阅读
The rapid approval of several novel agents,targeting the vascular endothelial growth factor or mammalian target of rapamycin pathways(sunitinib,pazopanib,sorafenib,axitinib,bevacizumab,everolimus,temsirolimus)has given to metastatic renal cell carcinoma(m